UB Paderborn / Katalog / Suche / in CDI

Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti‐DNA antibody tests

Arthritis and rheumatism, 2002-10, Vol.47 (5), p.546-555

2002

Volltextzugriff (PDF)

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Arthritis care & research (2010), 2012-05, Vol.64 (5), p.625-639

2012

Volltextzugriff (PDF)

SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1022

2018

Volltextzugriff (PDF)

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Arthritis and rheumatism, 2004-05, Vol.50 (5), p.1400-1411

2004

Volltextzugriff (PDF)

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Rheumatology (Oxford, England), 2012-07, Vol.51 Suppl 5 (suppl 5), p.v12-v21

2012

Volltextzugriff (PDF)

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2005-01, Vol.64 (1), p.52-55

2005

Volltextzugriff (PDF)

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Journal of the American Academy of Dermatology, 2009-07, Vol.61 (1), p.S1-S46

2009

Volltextzugriff (PDF)

FRI0153 Comparisons of work productivity and patient-reported outcomes through 78 weeks among optima study arms 2, 4, and 5

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.362-363

2013

Volltextzugriff (PDF)

Macromolecule tumor necrosis factor inhibitors: are more better?

Journal of rheumatology, 2005-12, Vol.32 (12), p.2285

Kavanaugh, Arthur F

2005

Volltextzugriff (PDF)

ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE

ANNALS OF THE RHEUMATIC DISEASES, 2013, Vol.72, p.228

2013

Volltextzugriff (PDF)

ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITIS

Rheumatic diseases clinics of North America, 1998-08, Vol.24 (3), p.593-614

Kavanaugh, Arthur F.

1998

Volltextzugriff (PDF)

Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit

The Journal of immunology (1950), 1995-11, Vol.155 (10), p.5029-5037

1995

Volltextzugriff (PDF)

Rheumatoid arthritis in the elderly: Is it a different disease?

The American journal of medicine, 1997-12, Vol.103 (6), p.S40-S48

Kavanaugh, Arthur F.

1997

Volltextzugriff (PDF)

Cutting edge diagnostics in rheumatology: The role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology

Arthritis and rheumatism, 2004-04, Vol.51 (2), p.291-298

2004

Volltextzugriff (PDF)

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Arthritis and rheumatism, 2006-01, Vol.54 (1), p.26-37

2006

Volltextzugriff (PDF)

Biologic Therapies for the Treatment of Asthma

Clinics in chest medicine, 2006-03, Vol.27 (1), p.133-147

2006

Volltextzugriff (PDF)

A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis

Journal of rheumatology, 1996-08, Vol.23 (8), p.1338

1996

Volltextzugriff (PDF)

COMPARISONS OF WORK PRODUCTIVITY AND PATIENT-REPORTED OUTCOMES THROUGH 78 WEEKS AMONG OPTIMA STUDY ARMS 2, 4, AND 5

ANNALS OF THE RHEUMATIC DISEASES, 2013, Vol.71, p.362

2013

Volltextzugriff (PDF)

Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2

The Journal of immunology (1950), 1994-06, Vol.152 (12), p.5703-5713

1994

Volltextzugriff (PDF)

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)

Annals of the rheumatic diseases, 2000-11, Vol.59 (suppl 1), p.i1-i2

2000

Volltextzugriff (PDF)

Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones

The Journal of immunology (1950), 1991-06, Vol.146 (12), p.4149-4156

1991

Volltextzugriff (PDF)

Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis

The Journal of immunology (1950), 1995-04, Vol.154 (7), p.3525-3537

1995

Volltextzugriff (PDF)

Guidelines for immunologic laboratory testing in the rheumatic diseases: An introduction

Arthritis and rheumatism, 2002-08, Vol.47 (4), p.429-433

American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines

2002

Volltextzugriff (PDF)

An evidence-based medicine approach to the diagnosis and management of musculoskeletal complaints

The American journal of medicine, 1997-12, Vol.103 (6), p.S3-S6

1997

Volltextzugriff (PDF)

Evidence-based use of rheumatologic laboratory tests

Archives of internal medicine (1960), 2004-01, Vol.164 (1), p.109

Kavanaugh, Arthur F

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti‐DNA antibody tests

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

SAT0316 Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life in patients with active psoriatic arthritis

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

FRI0153 Comparisons of work productivity and patient-reported outcomes through 78 weeks among optima study arms 2, 4, and 5

Macromolecule tumor necrosis factor inhibitors: are more better?

ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE

ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITIS

Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit

Rheumatoid arthritis in the elderly: Is it a different disease?

Cutting edge diagnostics in rheumatology: The role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Biologic Therapies for the Treatment of Asthma

A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis

COMPARISONS OF WORK PRODUCTIVITY AND PATIENT-REPORTED OUTCOMES THROUGH 78 WEEKS AMONG OPTIMA STUDY ARMS 2, 4, AND 5

Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)

Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones

Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis

Guidelines for immunologic laboratory testing in the rheumatic diseases: An introduction

An evidence-based medicine approach to the diagnosis and management of musculoskeletal complaints

Evidence-based use of rheumatologic laboratory tests

Suchergebnisse filtern